Penumbra designs, develops, manufactures, and markets medical devices. The Company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies, aspiration based thrombectomy systems and accessory devices, and revascularization device for mechanical thrombectomy. It also provides neurovascular embolization coiling systems and neurovascular stents. In addition, the Company offers neurosurgical aspiration tools and detachable embolic coil systems and microcatheter devices.

Employee Rating

3.3More
TypePublic
HQAlameda, US
Founded2004
Size (employees)1,700 (est)+14%
Websitepenumbrainc.com
Penumbra was founded in 2004 and is headquartered in Alameda, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Penumbra Office Locations

Penumbra has offices in Alameda, Darlinghurst, Berlin, New York and in 6 other locations
Alameda, (HQ)
1321 Harbor Bay Parkway
Alameda,
One Penumbra Place
Darlinghurst,
Suite 3, Level 5, 1 Oxford Street
Sao Paulo,
Royal Office Jardins Building, Suite 201 Avenida Brigadeiro Luis Antonio, 3421 Jardim Paulista
Berlin,
Am Borsigturm 44
Show all (12)
Report incorrect company information

Penumbra Financials and Metrics

Penumbra Revenue

Penumbra's revenue was reported to be $333.76 m in FY, 2017
USD

Revenue (Q3, 2018)

111.8m

Gross profit (Q3, 2018)

75.0m

Gross profit margin (Q3, 2018), %

67.1%

Net income (Q3, 2018)

(22.4m)

EBIT (Q3, 2018)

(20.8m)

Market capitalization (4-Dec-2018)

4.8b

Closing stock price (4-Dec-2018)

139.3

Cash (30-Sep-2018)

47.7m
Penumbra's current market capitalization is $4.8 b.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

186.1m263.3m333.8m

Revenue growth, %

41%

Cost of goods sold

62.0m92.5m116.6m

Gross profit

124.1m170.8m217.1m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

50.4m57.9m65.1m67.2m73.2m80.6m83.9m102.7m109.6m111.8m

Cost of goods sold

16.9m18.0m23.6m24.3m25.5m29.7m29.1m36.1m37.4m36.8m

Gross profit

33.5m39.9m41.5m42.9m47.7m50.9m54.8m66.6m72.3m75.0m

Gross profit Margin, %

66%69%64%64%65%63%65%65%66%67%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

19.5m13.2m50.6m

Accounts Receivable

57.2m47.7m

Inventories

56.8m73.0m94.9m

Current Assets

244.4m263.8m382.2m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

2.4m14.8m4.7m

Depreciation and Amortization

1.8m2.3m3.8m

Inventories

(25.1m)(19.7m)(18.8m)

Accounts Payable

132.0k1.4m1.9m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

732.0k780.0k965.0k(141.0k)(3.1m)(4.7m)(4.4m)5.5m18.9m

Depreciation and Amortization

1.2m538.0k1.1m1.8m654.0k1.4m2.6m1.4m2.9m4.5m

Inventories

(18.0m)(9.1m)(12.0m)(14.0m)(6.1m)(6.8m)(14.7m)208.0k(3.9m)(15.4m)

Accounts Payable

1.5m1.4m1.3m947.0k889.0k293.0k873.0k622.0k625.0k1.7m
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Penumbra Online and Social Media Presence

Embed Graph
Report incorrect company information

Penumbra News and Updates

Penumbra, Inc. to Present at the BMO Prescriptions for Success Healthcare Conference

ALAMEDA, Calif., Nov. 29, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BMO Prescriptions for Success Healthcare Conference in New York, NY on Wednesday, December 12, 2018. Event: BMO Prescriptions for Success...

Global Interventional Neurology Market Development Status and Growth Forecast 2024 Analysis By Medtronic, Inc. (Covidien), Penumbra, Inc., Stryker Corporation, Johnson & Johnson and Terumo Corporation

Summary This report includes market status and forecast of global and major regions, with the introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twitter @Indu…

Penumbra, Inc. Schedules Third Quarter 2018 Earnings Release and Conference Call for November 5, 2018

ALAMEDA, Calif., Oct. 15, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2018 after market close on Monday, November 5, 2018 at 5:00 PM Eastern Time. A press release with third quarter...

Neurovascular Devices 2018 Global Market Key Players – Stryker Corporation, Johnson & Johnson, Medtronic, Terumo, Penumbra – Analysis and Forecast to 2025

WiseGuyRerports.com Presents “Global Neurovascular Devices Market Research Report 2018” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

Penumbra, Inc. Reports Second Quarter 2018 Financial Results

ALAMEDA, Calif., Aug. 7, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2018. Revenue of $109.6 million in the second quarter of 2018, an increase of...
Show more
Report incorrect company information

Penumbra Company Life and Culture

Report incorrect company information

Penumbra Frequently Asked Questions

  • When was Penumbra founded?

    Penumbra was founded in 2004.

  • How many employees does Penumbra have?

    Penumbra has 1,700 employees.

  • What is Penumbra revenue?

    Latest Penumbra annual revenue is $333.8 m.

  • What is Penumbra revenue per employee?

    Latest Penumbra revenue per employee is $196.3 k.

  • Who are Penumbra competitors?

    Competitors of Penumbra include Stryker, Obalon Therapeutics and E-Qure.

  • Where is Penumbra headquarters?

    Penumbra headquarters is located at 1321 Harbor Bay Parkway, Alameda.

  • Where are Penumbra offices?

    Penumbra has offices in Alameda, Darlinghurst, Berlin, New York and in 6 other locations.

  • How many offices does Penumbra have?

    Penumbra has 12 offices.